FPF
ESPR

FNY Partners Fund’s Esperion Therapeutics ESPR Stock Holding History

FNY Partners Fund’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-500
Closed -$17K – 732
2017
Q1 		$17K Buy
+500
New +$11.4K ﹤0.01% 988

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Partners Fund's ESPR Position: Q2 2017 in Review

FNY Partners Fund sold out of Esperion Therapeutics (ESPR) in Q2 2017, closing a stake of 500 shares — an estimated $17K sold.

FNY Partners Fund first reported a position in ESPR in Q1 2017 and held it in 1 quarter. The position peaked at $17K in Q1 2017. 131 funds tracked by Wall St. Rank hold ESPR as of Q2 2017.

  • FNY Partners Fund reported no remaining Esperion Therapeutics position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 500 Esperion Therapeutics shares in Q2 2017, an estimated $17K.
  • FNY Partners Fund first reported a position in Esperion Therapeutics in Q1 2017 and held it in 1 quarter.
  • FNY Partners Fund's Esperion Therapeutics position peaked at $17K in Q1 2017.
  • 131 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.